The Role of the Endocrine Glands in Ketosis—I. The Ketosis of Fasting

por Amatruda, Thomas T., Engel, Frank L.
Publicado 1959

Randomized phase II trial of autologous dendritic cell vaccines versus autologous tumor cell vaccines in metastatic melanoma: 5-year follow up and additional analyses

por Dillman, Robert O., Cornforth, Andrew N., Nistor, Gabriel I., McClay, Edward F., Amatruda, Thomas T., Depriest, Carol
Publicado 2018

Observational study of talimogene laherparepvec use for melanoma in clinical practice in the United States (COSMUS-1)

por Perez, Matthew C, Zager, Jonathan S, Amatruda, Thomas, Conry, Robert, Ariyan, Charlotte, Desai, Anupam, Kirkwood, John M, Treichel, Sheryl, Cohan, David, Raskin, Leon
Publicado 2019

Superiority of dendritic cell vaccine vs tumor cell vaccine: survival by stratification subsets in MACVAC randomized Phase II trial of patient-specific vaccines utilizing antigens...

por Dillman, Robert O, McClay, Edward, Amatruda, Thomas, Semeniuk, George, Haskins, Clark, Weber, Robert, Burtzo, David, DePriest, Carol, Carbonell, Denysha, Cornforth, Andrew
Publicado 2015

Systemic versus local responses in melanoma patients treated with talimogene laherparepvec from a multi-institutional phase II study

por Kaufman, Howard L., Amatruda, Thomas, Reid, Tony, Gonzalez, Rene, Glaspy, John, Whitman, Eric, Harrington, Kevin, Nemunaitis, John, Zloza, Andrew, Wolf, Michael, Senzer, Neil N.
Publicado 2016

Dendritic Versus Tumor Cell Presentation of Autologous Tumor Antigens for Active Specific Immunotherapy in Metastatic Melanoma: Impact on Long-Term Survival by Extent of Disease at...

por Dillman, Robert O., McClay, Edward F., Barth, Neil M., Amatruda, Thomas T., Schwartzberg, Lee S., Mahdavi, Khosrow, de Leon, Cristina, Ellis, Robin E., DePriest, Carol
Publicado 2015

Biodistribution, shedding, and transmissibility of the oncolytic virus talimogene laherparepvec in patients with melanoma

por Andtbacka, Robert H.I., Amatruda, Thomas, Nemunaitis, John, Zager, Jonathan S., Walker, John, Chesney, Jason A., Liu, Kate, Hsu, Cheng-Pang, Pickett, Cheryl A., Mehnert, Janice M.
Publicado 2019

Patterns of Clinical Response with Talimogene Laherparepvec (T-VEC) in Patients with Melanoma Treated in the OPTiM Phase III Clinical Trial

por Andtbacka, Robert H. I., Ross, Merrick, Puzanov, Igor, Milhem, Mohammed, Collichio, Frances, Delman, Keith A., Amatruda, Thomas, Zager, Jonathan S., Cranmer, Lee, Hsueh, Eddy, Chen, Lisa, Shilkrut, Mark, Kaufman, Howard L.
Publicado 2016

Cutaneous head and neck melanoma in OPTiM, a randomized phase 3 trial of talimogene laherparepvec versus granulocyte‐macrophage colony‐stimulating factor for the treatment of unres...

por Andtbacka, Robert H. I., Agarwala, Sanjiv S., Ollila, David W., Hallmeyer, Sigrun, Milhem, Mohammed, Amatruda, Thomas, Nemunaitis, John J., Harrington, Kevin J., Chen, Lisa, Shilkrut, Mark, Ross, Merrick, Kaufman, Howard L.
Publicado 2016

Final planned overall survival (OS) from OPTiM, a randomized Phase III trial of talimogene laherparepvec (T-VEC) versus GM-CSF for the treatment of unresected stage IIIB/C/IV melan...

por Andtbacka, Robert HI, Collichio, Frances A, Amatruda, Thomas, Senzer, Neil, Chesney, Jason, Delman, Keith, Spitler, Lynn, Puzanov, Igor, Agarwala, Sanjiv, Milhem, Mohammed, Harrington, Kevin, Middleton, Mark, Li, Ai, Shilkrut, Mark, Coffin, Robert, Kaufman, Howard
Publicado 2014